YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).